New Advances in Drugs/Vaccines against Infectious Diseases

Dear Colleagues,

Infectious diseases are a serious and growing public health problem worldwide, causing high mortality and morbidity. They are caused by different classes of pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites. Based on the nature of a pathogen, it can spread from person to person, from animal to human, or through other means, such as air, water, food, or soil. We already have complicated diseases like AIDS, tuberculosis, malaria, etc. to deal with, which affect a greater population of people worldwide. The recent COVID-19 pandemic taught us a lesson by taking more than 6.9 million human lives, where the USA alone has seen more than 1 million deaths. Even though we have ultra-modern technologies, there are many complications in finding solutions to these infectious diseases. To overcome these obstacles, we are in need of efficient and timely treatments with potential drugs or vaccines. Pathogens cause diseases that range from being mild to life-threatening, and this topic focuses specifically on infections that spread in hospitals and other healthcare settings, infections that are resistant to antibiotics, emerging or re-emerging infectious diseases, infectious diseases with a lack of vaccines, multidrug-resistant pathogens, tuberculosis, and COVID-19.

We foresee that our research topic will bring all novel research against infectious diseases together in one place. We welcome potential topics for submission to this Special Issue, including (but not limited to) the following:

1. Antimicrobial drugs: natural, synthetic, repurposed, nanoparticle-based, etc.
2. Vaccines: recombinant, DNA vaccine, prime boost, mRNA, live attenuated vaccine, etc.
3. System biology approach in drug/vaccine development.
4. Discovery of drugs/vaccine molecular mechanisms using omics technologies—genomics, proteomics, and metabolomics.
5. New approaches in drug/vaccine development against COVID-19 and tuberculosis.
6. Study of host microbiome after microbial infection or drug/vaccine treatment.

Dr. Raja Veerapandian
Dr. Jagdish Joshi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Infectious Disease Reports is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• infectious diseases
• drugs
• vaccines
• in silico
• system biology
• multi-omics
• microbiome
• COVID-19
• tuberculosis